Education
About Us
Working with TipRanks
Follow Us
Tharimmune (THAR)
NASDAQ:THAR
THAR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $6.39
Previous CloseN/A
Volume24.91K
Average Volume (3M)42.25K
Market Cap
$5.61M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.68
Shares Outstanding4,635,251
10 Day Avg. Volume37,512
30 Day Avg. Volume42,251
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.00Price Target Upside1249.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Tharimmune News
THAR FAQ
What was Tharimmune’s price range in the past 12 months?
Tharimmune lowest stock price was $0.95 and its highest was $6.39 in the past 12 months.
What is Tharimmune’s market cap?
Tharimmune’s market cap is $5.61M.
When is Tharimmune’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tharimmune’s earnings last quarter?
Currently, no data Available
Is Tharimmune overvalued?
According to Wall Street analysts Tharimmune’s price is currently Undervalued.
Does Tharimmune pay dividends?
Tharimmune does not currently pay dividends.
What is Tharimmune’s EPS estimate?
Tharimmune’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tharimmune have?
Tharimmune has 4,635,251 shares outstanding.
What happened to Tharimmune’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tharimmune?
Currently, no hedge funds are holding shares in THAR
Company Description
Tharimmune
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Tharimmune (THAR) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
Ownership Overview
22.47% Insiders
0.16% Mutual Funds
0.24% Other Institutional Investors
77.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---